ArticleThe American journal of tropical medicine and hygiene2017
Field Trial of the CareStart Biosensor Analyzer for the Determination of Glucose-6-Phosphate Dehydrogenase Activity in Haiti.
Article in The American journal of tropical medicine and hygiene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Performance of quantitative point-of-care tests to measure G6PD activity: An individual participant data meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review.Frontiers in genetics · 2023Pooled it
- Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.Malaria journal · 2018Trial
- [Expansion of the use of technologies to reduce cases of malaria due to Plasmodium vivax in the Brazilian Amazon: a budget impact analysis].Cadernos de saude publica · 2026Article
- Article
- Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.Malaria journal · 2023Article
- A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria.Pathogens (Basel, Switzerland) · 2023Review
- Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.Malaria journal · 2022Article
- G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study.PloS one · 2022Article
- Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania.Infectious diseases of poverty · 2021Article
- Differences in factors associated with anemia in Haitian children from urban and rural areas.PloS one · 2021Article
- Tafenoquine and G6PD: a primer for clinicians.Journal of travel medicine · 2019Review
- The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis.Wellcome open research · 2019Article
- Low and heterogeneous prevalence of glucose-6-phosphate dehydrogenase deficiency in different settings in Ethiopia using phenotyping and genotyping approaches.Malaria journal · 2018Article
- Primaquine-induced haemolysis in females heterozygous for G6PD deficiency.Malaria journal · 2018Review
- Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood.PloS one · 2018Article
- Methods for the field evaluation of quantitative G6PD diagnostics: a review.Malaria journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Throughout many developing and tropical countries around the world, malaria remains a significant threat to human health. One barrier to malaria elimination is the ability to safely administer primaquine chemotherapy for the radical cure of malaria infections in populations with a high prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency. In the current study, a field trial of the world's first quantitative, point-of-care assay for measuring G6PD activity was conducted in Haiti. The performance of the CareStart Biosensor Analyzer was compared with the gold standard spectrophotometric assay and genotyping of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.